Key result
Intracoronary adenosine administered before and after stenting reduced the rate of no-reflow compared to placebo in patients with STEMI.
Why the study?
The no-reflow phenomenon deteriorates clinical outcomes following PCI, and intracoronary adenosine was investigated as a potential therapy to prevent it.
Does intracoronary adenosine reduce the no-reflow phenomenon in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention?
RCT (n=104)
Does intracoronary adenosine reduce the no-reflow phenomenon in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention?
Intracoronary adenosine administered before and after stenting reduces angiographic no-reflow in STEMI patients, but does not significantly improve ST-segment resolution or 30-day clinical outcomes.
Answers are grounded in this paper and cite their sources.
IC adenosine reduces angiographic no-reflow in STEMI PCI; confirms surrogate benefit but leaves clinical outcomes open.
No-reflow phenomenon as a serious complication following percutaneous coronary intervention, deteriorates clinical outcomes. Intracoronary (IC) Adenosine, seems to be a way to deal with it. One hundred four consecutive patients with ST-segment elevation myocardial infarction were randomized into two groups. Each group consisted of 52 patients who managed with two bolus doses of IC Adenosine (Adenosine group) or two bolus doses of IC normal saline (placebo group) administered before and after stenting. Thrombolysis in myocardial infarction (TIMI) grade flow, ST-segment resolution (STR) and post-procedural clinical outcomes were used as endpoints. IC adenosine led to lower rates of no-reflow based on TIMI grade flow scaling (15.4% vs. 44.3%; P-value: 0.02). STR classified as complete, partial and no resolution was similar between two groups (P-value: 0.748). Also, post-interventional clinical outcomes, including arrhythmia, left ventricular ejection fraction, hospitalization time, and 30 days mortality were similar between Adenosine and placebo groups.
No takes yet. Share an insight, caveat, or question.
Naghshtabrizi et al. (2020) conducted an RCT in ST-segment elevation myocardial infarction (n=104). Intracoronary adenosine vs. Intracoronary normal saline (placebo) was evaluated on No-reflow based on TIMI grade flow scaling (p=0.02). Intracoronary adenosine administered before and after stenting reduced the rate of no-reflow compared to placebo in patients with STEMI.
Synapse has enriched 10 related papers. Consider them for comparative context: